VRTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
3.3B
+11.6%
3.0B
-6.4%
3.2B
+3.7%
3.1B
+3.8%
3.0B
Cost of Revenue
489.2M
+24.5%
392.8M
-15.7%
466.0M
+12.3%
414.8M
+1.8%
407.5M
Gross Profit
2.8B
+9.7%
2.6B
-4.8%
2.7B
+2.3%
2.7B
+4.1%
2.6B
Operating Expenses
1.6B
+9.7%
1.5B
-4.1%
1.5B
+2.9%
1.5B
+4.9%
1.4B
R&D
993.8M
+3.3%
961.6M
-1.2%
973.7M
-0.4%
977.7M
-0.1%
978.4M
SG&A
582.2M
+17.9%
493.7M
+1.4%
487.0M
+9.4%
445.1M
+4.8%
424.6M
Operating Income
1.2B
+9.6%
1.1B
-5.6%
1.2B
+1.7%
1.2B
+3.0%
1.2B
EBITDA
1.3B
+10.9%
1.2B
-9.4%
1.3B
+1.8%
1.3B
+7.4%
1.2B
Net Income
1.1B
+6.6%
1.0B
-13.4%
1.2B
+10.0%
1.1B
+4.8%
1.0B
EPS (Basic)
$4.34
+6.9%
$4.06
-13.6%
$4.70
+10.8%
$4.24
+5.5%
$4.02
EPS (Diluted)
$4.31
+7.2%
$4.02
-13.5%
$4.65
+10.7%
$4.20
+5.3%
$3.99
Shares (Diluted)
255.2M
-0.4%
256.3M
+0.1%
256.0M
-0.6%
257.6M
-0.5%
258.9M
Vertex Pharmaceuticals (VRTX) โ€” Financials